Dupont et al. assessed serum YKL40 levels in healthy individuals, those at a high risk of ovarian cancer, and those with EOC, finding that preoperative YKL40 levels were elevated in 72% of patients with ovarian cancer, outperforming CA125 levels, which were elevated in 46% [61]. This evidence concerns the gene CHI3L1 and ovarian cancer.